Osteogenesis imperfecta type 3
MONDO:0009804Osteogenesis imperfecta type III is a severe type of osteogenesis imperfecta (OI), a genetic disorder characterized by increased bone fragility, low bone mass and susceptibility to bone fractures. The main signs of type III include very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta (DI).
Also known as: OI type 3, OI3, osteogenesis imperfecta type 3, osteogenesis imperfecta type III, progressive deforming osteogenesis imperfecta, severe osteogenesis imperfecta, OI type III, OI, type 3
44 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug aims to strengthen bones in kids with rare brittle bone disease
Disease control OngoingThis phase 3 study tests setrusumab, a monthly IV infusion, in 6 Japanese children with osteogenesis imperfecta (types I, III, or IV), a condition that causes fragile bones and frequent fractures. The main goal is to see if the drug lowers the number of fractures, including spine…
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to slash fractures in brittle bone disease
Disease control OngoingThis study tests a medicine called setrusumab in people with osteogenesis imperfecta (brittle bone disease). The goal is to see if it can lower the number of bone fractures. About 183 participants with types I, III, or IV of the disease who have had recent fractures will receive …
Phase: PHASE2, PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug aims to cut fractures in kids with brittle bones
Disease control OngoingThis study tests a new medicine called setrusumab against standard bone-strengthening drugs (bisphosphonates) in children aged 2 to under 7 with osteogenesis imperfecta (brittle bone disease) types I, III, or IV. The goal is to see if setrusumab can lower the number of bone break…
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Fetal stem cells aim to mend broken bones in infants
Disease control OngoingThis early-phase trial tests whether fetal stem cells given before or after birth can safely help infants with severe osteogenesis imperfecta, a genetic condition causing fragile bones and frequent fractures. Up to 18 children will receive multiple doses of the cells. The main go…
Phase: PHASE1, PHASE2 • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
Weekly Check-Ins could boost patient satisfaction for chronic pain
Knowledge-focused TerminatedThis study looked at whether having more frequent contact with a clinician (at least once a week) improves satisfaction for people with long-lasting musculoskeletal conditions. Participants were split into two groups: one with standard contact and one with extra check-ins via tex…
Phase: NA • Sponsor: University of Texas at Austin • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can a special clinic get workers back on the job faster? norway launches massive study.
Knowledge-focused OngoingThis study tests whether a Norwegian clinic (NSAC) helps people with common mental health issues or muscle pain return to work sooner. 2500 adults are split into three groups: one gets treatment quickly, one waits 10-14 weeks, and one gets a basic check-up. Researchers will track…
Phase: NA • Sponsor: Nordlandssykehuset HF • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Massive PT study mines 4 million records to find what works best
Knowledge-focused OngoingThis study looks back at the medical records of about 4 million people who had physical or occupational therapy for muscle and joint problems. Researchers want to see if different ways of giving therapy lead to different results. No new treatments are tested—the goal is to learn …
Sponsor: ATI Holdings, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Phone app vs. doctor: can a mobile tool catch infections after surgery?
Knowledge-focused TerminatedThis study aimed to see if a mobile monitoring tool could accurately identify surgical site infections (SSIs) in orthopedic surgery patients, compared to the usual manual review. The study was withdrawn before enrolling any participants, so no results are available. It was design…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC